dc.contributor.author | Schifano, Fabrizio | |
dc.contributor.author | Guarino, Valentina | |
dc.contributor.author | Papanti, Duccio G. | |
dc.contributor.author | Baccarin, Jacopo | |
dc.contributor.author | Orsolini, Laura | |
dc.contributor.author | Corkery, John M. | |
dc.date.accessioned | 2019-10-29T01:06:16Z | |
dc.date.available | 2019-10-29T01:06:16Z | |
dc.date.issued | 2017-05-18 | |
dc.identifier.citation | Schifano , F , Guarino , V , Papanti , D G , Baccarin , J , Orsolini , L & Corkery , J M 2017 , ' Is there a potential of misuse for Magnolia officinalis compounds/metabolites? ' , Human Psychopharmacology: Clinical and Experimental , vol. 32 , no. 3 , e2595 . https://doi.org/10.1002/hup.2595 | |
dc.identifier.issn | 0885-6222 | |
dc.identifier.uri | http://hdl.handle.net/2299/21806 | |
dc.description | © 2017 John Wiley & Sons, Ltd. | |
dc.description.abstract | Objective: Magnolia bark contains magnolol, metabolized to tetrahydromagnolol and honokiol, with both GABA-ergic/cannabimimetic activities, hence of possible attraction to vulnerable individuals/recreational misusers. Methods: A literature review, assessment of related anecdotal online Magnolia misuse's reports and an overview of Magnolia products' online acquisition possibilities has been here described. Results: No peer-reviewed papers about Magnolia abuse/misuse/dependence/addiction were identified. Conversely, from a range of websites emerged potentially 3 groups of Magnolia misusers: (a) subjects with a psychiatric history already treated with benzodiazepines, being attracted to Magnolia bark as a “natural sedative”; (b) polydrug misusers, ingesting Magnolia with a range of other herbs/plants, attracted by the GABA-ergic/cannabimimetic activities; (c) subjects naive to the misusing drugs' scenario, perceiving Magnolia as a natural dietary supplement/weight-control compound. Conclusions: To the best of our knowledge, this is the first paper commenting on the possible Magnolia derivatives' potential of misuse. Magnolia's recent increase in popularity, mainly as a sedative, may be arguably due to its peculiar pharmacological properties/acceptable affordability levels/virtually worldwide favorable legal status and customers' attraction to a product being perceived as “natural” and hence somehow “safe.” Future/potent/synthetic magnolol and honokiol structural analogues could however contribute to increasing the number of synthetic GABA-ergic/cannabimimetic misusing compounds. | en |
dc.format.extent | 294270 | |
dc.language.iso | eng | |
dc.relation.ispartof | Human Psychopharmacology: Clinical and Experimental | |
dc.subject | herbal highs | |
dc.subject | honokiol | |
dc.subject | magnolol | |
dc.subject | Novel psychoactive substances | |
dc.subject | synthetic cannabinoids | |
dc.subject | THM | |
dc.subject | Neurology | |
dc.subject | Clinical Neurology | |
dc.subject | Psychiatry and Mental health | |
dc.subject | Pharmacology (medical) | |
dc.title | Is there a potential of misuse for Magnolia officinalis compounds/metabolites? | en |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | University of Hertfordshire | |
dc.description.status | Peer reviewed | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85019852108&partnerID=8YFLogxK | |
rioxxterms.versionofrecord | 10.1002/hup.2595 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |